Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phospholipase A2 and arthritis

J S Bomalaski1, M A Clark

  • 1Department of Medicine, Medical College of Pennsylvania, Philadelphia.

Arthritis and Rheumatism
|February 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Psychosocial Adjustment Measure for Persons With Upper Limb Amputation.

Canadian prosthetics & orthotics journal·2023
Same author

Quacks.

Atlanta journal-record of medicine·2022
Same author

Medical Organization.

Atlanta journal-record of medicine·2022
Same author

Entero-Colitis of Infancy.

Atlanta medical and surgical journal (1884)·2022
Same author

Two Cases of Concussion of the Brain.

Atlanta medical and surgical journal (1884)·2022
Same author

Design concepts for DNA-encoded library synthesis.

Bioorganic & medicinal chemistry·2021

Phospholipase A2 (PLA2) is central to inflammatory arthritis by releasing inflammatory lipids. Inhibitors targeting PLA2 show promise for treating arthritis, with new compounds progressing through clinical trials.

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Background:

  • Phospholipase A2 (PLA2) plays a critical role in releasing arachidonic acid, a precursor to inflammatory mediators like prostaglandins and leukotrienes.
  • Elevated PLA2 concentrations and activity are observed in inflammatory arthritis, particularly rheumatoid arthritis (RA).
  • Cytokines such as IL-1 and TNF, prevalent in RA synovial fluid, stimulate PLA2 activity, highlighting its central role in inflammation.

Purpose of the Study:

  • To review the expanding understanding of PLA2 beyond its enzymatic function.
  • To emphasize the established role of PLA2 in inflammatory arthritis.
  • To discuss the development of PLA2 inhibitors as potential therapeutic agents for arthritis.

Main Methods:

  • Literature review of studies on PLA2 function, its role in inflammatory arthritis, and the development of inhibitors.

Related Experiment Videos

  • Analysis of research on signal transduction pathways involving PLA2 and inflammatory cytokines.
  • Examination of findings from biotechnology and pharmaceutical companies regarding PLA2 inhibitors.

    • Main Results:

    • PLA2 is a rate-limiting enzyme in the production of inflammatory lipids and is implicated in inducing inflammation.
    • PLA2 activity is stimulated by key inflammatory cytokines found in RA patients.
    • Various PLA2 isoforms and regulatory human proteins have been identified, though their specific roles in arthritis require further elucidation.
    • Development of PLA2 inhibitors is a significant area of research with potential for clinical application.

    Conclusions:

    • PLA2 is a key mediator in inflammatory arthritis.
    • PLA2 inhibitors represent a promising therapeutic strategy for arthritis treatment.
    • Ongoing research and clinical trials are expected to yield new treatments for arthritis targeting PLA2 pathways.